Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
3119 articles with Eli Lilly and Company
-
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
5/11/2022
Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration has approved OLUMIANT® for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.
-
Mary Lynne Hedley Elected to Lilly Board of Directors
5/6/2022
The Board of Directors of Eli Lilly and Company has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022.
-
Life Science industries are seeing massive financial fluctuations in how they're handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
-
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
5/3/2022
Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022.
-
Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform
5/3/2022
Genesis Therapeutics announced that it has entered into a strategic collaboration with Eli Lilly and Company to discover novel therapies for up to five targets across a range of therapeutic areas.
-
Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.
-
Lilly Declares Second-Quarter 2022 Dividend
5/2/2022
The board of directors of Eli Lilly and Company has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock.
-
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
4/28/2022
Eli Lilly and Company announced its financial results for the first quarter of 2022.
-
Eli Lilly had a lucrative first quarter, with revenue growth rising 15% driven by sales of its diabetes drug Trulicity and its COVID-19 antibodies.
-
AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
4/26/2022
AMRA's quantitative body composition method was used in Eli Lilly and Company's magnetic resonance imaging (MRI) sub-study of the phase 3 SURPASS-3 clinical trial (trial NCT03882970) to assess the impact of tirzepatide (5 mg, 10 mg, 15 mg) on various fat depots in individuals with Type 2 Diabetes (T2DM).
-
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
4/25/2022
NeoGenomics, Inc. announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost.
-
Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
4/19/2022
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022.
-
The charges come from several in-process research and development projects acquired outside of a business combination.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
-
Eli Lilly has shared positive results of lebrikizumab combination therapy with topical corticosteroids, which is intended to treat atopic dermatitis (AD).
-
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
4/11/2022
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.
-
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
4/11/2022
Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and Company.
-
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
-
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
4/10/2022
Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers.